Somatostatinoma Withdrawn Phase 2 Trials for Dovitinib (DB05928)

Also known as: Somatostatinomas

IndicationStatusPhase
DBCOND0000820 (Somatostatinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02108782Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsTreatment